Shanghai Model Organisms Center, Inc. (SHA:688265)
53.77
-1.46 (-2.64%)
Oct 14, 2026, 11:29 AM CST
SHA:688265 Revenue
Shanghai Model Organisms Center had revenue of 132.52M CNY in the quarter ending June 30, 2026, with 23.43% growth. This brings the company's revenue in the last twelve months to 457.70M, up 14.38% year-over-year. In the year 2025, Shanghai Model Organisms Center had annual revenue of 421.02M with 10.44% growth. That makes Shanghai Model Organisms Center the 25,568th largest company in the world by revenue and 4,542nd in China.
Revenue (ttm)
457.70M
Revenue Growth
+14.38%
P/S Ratio
9.32
Revenue / Employee
477.27K
Employees
959
Market Cap
4.15B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 421.02M | 39.78M | 10.44% |
| Dec 31, 2024 | 381.24M | 14.69M | 4.01% |
| Dec 31, 2023 | 366.55M | 63.58M | 20.99% |
| Dec 31, 2022 | 302.97M | 27.70M | 10.06% |
| Dec 31, 2021 | 275.27M | 79.08M | 40.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 3.00B |
| Wuhan Hvsen Biotechnology | 1.72B |
| Hefei Lifeon Pharmaceutical | 1.51B |
| Kexing Biopharm | 1.44B |
| Shenzhen Weiguang Biological Products | 1.20B |
| ChemPartner PharmaTech | 1.16B |
| Beijing Konruns Pharmaceutical | 917.05M |
| Beijing Bohui Innovation Biotechnology Group | 816.14M |